Purpose There is currently no measure to predict a treatability of long-acting β-2 agonist
(LABA) or long-acting muscarinic antagonist (LAMA) in patients with chronic obstructive
pulmonary disease (COPD). We aimed to build prediction models for the treatment response
to these bronchodilators, in order to determine the most responsive medication for patients
with COPD. Methods We performed a prospective open-label crossover study, in which each
long-acting bronchodilator was given in a random order to 65 patients with stable COPD for …

Rationale: There is currently no measure to predict a treatability to a long-acting beta-2
agonist (LABA) or long-acting muscarinic antagonist (LAMA) in patients with COPD. We
aimed to build prediction models for the treatment response to these bronchodilators.
Methods: We performed a prospective crossover study, in which each long-acting
bronchodilator was given in a random order to 65 patients with stable COPD for 4 weeks,
with a washout period in between. We analyzed fourteen baseline clinical traits, expression …